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Akt Promotes Cell Survival by Phosphorylating
and Inhibiting a Forkhead Transcription Factor
1991). These cytokines, by binding to their cognate cell
surface receptors, may in turn induce caspase cascades
and thereby propagate the process of apoptosis (Na-
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Recently, a signaling pathway by which extracellular*Division of Neuroscience
stimuli suppress apoptosis has been characterized. Sur-Children's Hospital and Department of Neurobiology
vival factors, such as insulin-like growth factor 1 (IGF1)Harvard Medical School
and neurotrophins, bind to their cell surface receptorsBoston, Massachusetts 02115
and trigger the activation of several kinases, including²Department of Cell Biology
the phosphatidylinositol 3-kinase (PI3K) (Fruman et al.,Harvard Medical School
1998) and the Ca21/calmodulin-dependent kinase ki-Boston, Massachusetts 02115
nase (Yano et al., 1998). These kinases in turn lead to³Ludwig Institute for Cancer Research
the activation of a serine/threonine kinase termed AktUniversity of California at San Diego
or PKB (for reviews, Datta and Greenberg, 1998; Down-San Diego, California 92093
ward, 1998). Akt plays a central role in promoting the
survival of a wide range of cell types (Dudek et al.,
1997; Kauffmann-Zeh et al., 1997; Kennedy et al., 1997;
Summary Songyang et al., 1997). Recently, two Akt substrates
that are components of the intrinsic cell death machinery
Survival factors can suppress apoptosis in a transcrip- have been identified: the Bcl2 family member BAD (Datta
tion-independent manner by activating the serine/ et al., 1997; del Peso et al., 1997) and the protease
threonine kinase Akt, which then phosphorylates and Caspase 9 (Cardone et al., 1998; Y. Gotoh et al., unpub-
inactivates components of the apoptotic machinery, lished data). In both cases, phosphorylation of these
including BAD and Caspase 9. In this study, we demon- proteins by Akt suppresses their proapoptotic function,
strate that Akt also regulates the activity of FKHRL1, thereby accounting at least in part for the potent survival
a member of the Forkhead family of transcription fac- effects of Akt.
tors. In the presence of survival factors, Akt phosphor- If Akt is a general mediator of cell survival, it is possible
ylates FKHRL1, leading to FKHRL1's association with that this kinase catalyzes the phosphorylation of other
14-3-3 proteins and FKHRL1's retention in the cyto- substrates in addition to BAD and Caspase 9. One possi-
plasm. Survival factor withdrawal leads to FKHRL1 bility that remained to be examined was that Akt might
dephosphorylation, nuclear translocation, and target phosphorylate and regulate the activity of transcription
gene activation. Within the nucleus, FKHRL1 triggers factors that control cell death genes. This hypothesis is
apoptosis most likely by inducing the expression of supported by the observation that Akt translocates into
genes that are critical for cell death, such as the Fas the nucleus upon exposure of cells to survival factors
ligand gene. (Andjelkovic et al., 1997). Although Akt targets within
the nucleus remained to be identified, genetic studies
of the PI3K/Akt signaling pathway in the nematode
Introduction Caenorhabditis elegans have established that this sig-
naling cascade suppresses the function of the transcrip-
Survival factors suppress the intrinsic cell death machin- tion factor DAF16, which belongs to the Forkhead family
ery and thereby prevent apoptosis, a naturally occuring (FH) (Lin et al., 1997; Ogg et al., 1997; Paradis and Ruv-
cell death process that is critical for the development kun, 1998). Analysis of the DAF16 sequence reveals
of multicellular organisms (Jacobson et al., 1997). Exe- three sites that conform to the consensus site phosphor-
cution of apoptosis is ensured by a series of transcrip- ylated by Akt (RXRXXS/T) (Alessi et al., 1996), sug-
tion-independent events that include the activation of gesting that DAF16 and perhaps other FH transcription
cascades of cysteine proteases, termed caspases, and factors might be direct targets of Akt.
result in cell disintegration followed by engulfment by Three members of the human FH family, termed FKHR
surrounding cells (for review, Steller, 1995). Under some (Galili et al., 1993), FKHRL1 (Hillion et al., 1997; Anderson
circumstances, apoptosis is a transcription-dependent et al., 1998), and AFX (Borkhardt et al., 1997), are similar
process that requires the upregulation of death genes, in sequence to DAF16 and represent the mammalian
including the tumor suppressor p53 (Khanna and Lavin, counterparts of DAF16 (Ogg et al., 1997). The genes for
1993), the proapoptotic member of the Bcl2 family Bax these human DAF16 homologs were first identified at
chromosomal breakpoints in human tumors (Galili et al.,(Miyashita and Reed, 1995), and certain cytokines, such
1993; Borkhardt et al., 1997; Hillion et al., 1997; Andersonas the Fas ligand (Friesen et al., 1996; Kasibhatla et al.,
et al., 1998). Notably, the three putative Akt phosphoryla-1998; Le-Niculescu et al., 1999) or TNFa (Sung et al.,
tion sites present in the DAF16 sequence are also found
in the human homologs, raising the possibility that these§ To whom correspondence should be addressed (e-mail: green
human DAF16 counterparts might also be Akt targets.berg@a1.tch.harvard.edu).
In the present study, we show that human FKHRL1‖ Present address: Department of Neurology, University of Pitts-
burgh, Pittsburgh, Pennsylvania 15213. is a direct target of Akt phosphorylation and that Akt
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phosphorylation of FKHRL1 results in FKHRL1 retention
in the cytoplasm and the inhibition of FKHRL1-depen-
dent transcription. Survival factor withdrawal induces
FKHRL1 dephosphorylation and translocation to the nu-
cleus. Within the nucleus, the dephosphorylated FKHRL1
induces target genes such as Fas ligand and triggers
apoptosis. We propose that growth factors, by triggering
the Akt-dependent phosphorylation and inactivation of
FKHRL1 function, suppress the transcription of death
genes, such as the Fas ligand gene, and thereby pro-
mote cell survival.
Results
Akt Phosphorylates FKHRL1 In Vitro
We initially tested the FKHRL1 isoform as an Akt sub-
strate, since Northern blot experiments had shown that
the FKHRL1 mRNA is the most ubiquitously expressed
of the three mammalian DAF16 homologs (Anderson et
al., 1998). To determine whether FKHRL1 is a substrate
of Akt in vitro, we produced in bacteria a GST-FKHRL1
fusion protein and a series of mutants in which one or
three of the putative Akt phosphorylation sites (T32, Figure 1. Akt Phosphorylates FKHRL1 In Vitro
S253, and S315) were replaced by a nonphosphorylat-
(A) A constitutively active form of Akt (c.a.) or kinase inactive mutant
able alanine residue. A constitutively active form of Akt (k.n.) expressed in 293T cells was immunoprecipitated with the anti-
immunoprecipitated from 293T cells effectively phos- HA antibody and incubated in the presence of 32P-ATP and 5 mg of
phorylated wild-type GST-FKHRL1 in an in vitro kinase GST-FKHRL1 fusion proteins, wild type (WT), T32A/S253A/S315A
triple mutant (TM), or each of the single mutants. L, full-length GST-assay (Figure 1A). FKHRL1 phosphorylation by Akt re-
FKHRL1 protein; T, smaller fragment of the GST-FKHRL1 proteinquired the presence of active Akt in the immune com-
that is possibly a degradation product.plex, since an inactive form of Akt was unable to phos-
(B) Samples obtained in (A) were analyzed by immunoblot with the
phorylate the FKHRL1 protein (Figure 1A). antibodies directed against phospho-T32 FKHRL1 (top panel) or
To determine whether Akt phosphorylates FKHRL1 at phospho-S253 FKHRL1 (middle panel) or with the antibody directed
T32, S253, and/or S315, we tested as Akt substrates against total FKHRL1 (bottom panel).
mutants of FKHRL1 in which just one of these sites was
converted to an alanine (Figure 1A). Whereas the S315A phosphorylated at T32 and demonstrate that Akt phos-
mutant was phosphorylated to the same extent as the phorylates FKHRL1 at T32 in vitro. By a similar strategy,
wild-type FKHRL1 protein, the T32A and the S253A mu- we demonstrated that the anti-phospho S253 antibody
tants were phosphorylated at a significantly lower level, is specific to FKHRL1 that is phosphorylated at S253
indicating that T32 and S253 of FKHRL1 are likely to be and that Akt phosphorylates FKHRL1 at S253 in vitro
Akt targets. However, both the T32A and S253A mutants (Figure 1B, middle panel).
displayed residual phosphorylation by Akt (Figure 1A),
suggesting that when one of these sites is mutated, the Akt Phosphorylates FKHRL1 In Vivo
other site is still phosphorylated. By contrast, a FKHRL1 To determine whether Akt phosphorylates FKHRL1 at
protein in which all three of the putative Akt phosphory- T32, S253, and/or S315 within cells, we generated HA
lation sites were converted to alanines was no longer epitope±tagged versions of wild-type and phosphoryla-
detectably phosphorylated by Akt (Figure 1A), indicating tion mutants of FKHRL1. These constructs were trans-
that there are no other sites within FKHRL1 that are fected into 293T cells and the expression of FKHRL1
significantly phosphorylated by Akt in vitro. monitored by immunoblotting with an anti-FKHRL1 anti-
To confirm that T32 and S253 are the sites of Akt- body (Figure 2A, bottom panel). The phosphorylation of
catalyzed phosphorylation in vitro, we raised antibodies FKHRL1 at T32 or S253 was monitored by immunoblot-
to phosphopeptides that correspond to these two phos- ting with anti-phospho FKHRL1-specific antibodies (Fig-
phorylation sites and used the antibodies in immu- ure 2A, top and middle panels). When 293T cells were
noblotting experiments (Figure 1B). The anti-phospho grown in the presence of growth factors, the anti-phos-
T32 peptide antibody recognized wt FKHRL1 that was pho T32 and anti-phospho S253 antibodies recognized
incubated with a constitutively active form of Akt in an wild-type FKHRL1 but not the corresponding single mu-
in vitro kinase assay but failed to recognize unphosphor- tants (T32A and S235A, respectively), the corresponding
ylated FKHRL1 (Figure 1B, top panel). Moreover, the double mutants, or the triple mutant of FKHRL1 (Figure
anti-phospho T32 antibody did not recognize FKHRL1 2A). These findings confirm the specificity of the anti-
in which T32 had been converted to an alanine, but it phospho T32 and anti-phospho S253 antibodies and
was able to effectively recognize FKHRL1 in which S253 indicate that in the presence of growth factors, condi-
or S315 was converted to an alanine (Figure 1B, top tions under which the PI3K/Akt pathway is active,
panel). These findings indicate that the anti-phospho FKHRL1 is phosphorylated within cells at both T32 and
S253.T32 antibody specifically recognizes FKHRL1 when it is
Akt Phosphorylates FKHRL1
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Figure 2. Akt Induces Phosphorylation of FKHRL1 In Vivo
(A) 293T cells were transiently transfected with constructs encoding FKHRL1 tagged with the HA epitope (WT or mutants) or with an empty
vector (CTL). Whole-cell extracts were resolved by SDS±PAGE and immunoblotted with the antibodies directed against phospho-T32 (top
panel) or phospho-S253 (middle panel). The total level of protein was assayed by immunoblot using the anti-FKHRL1 antibody (bottom panel).
(B) CCL39 fibroblasts were transiently cotransfected with wt FKHRL1 plasmid and an empty vector (CTL) or a constitutively active Akt construct
(c.a.). They were serum starved for 20 hr, then incubated with 10 mM LY for 1 hr and stimulated with 50 ng/ml IGF1 for 20 min. Cell lysates
were analyzed by immunoblot with the antibodies directed against phospho-T32 (top panel) or phospho-S253 (middle panel). The total level
of protein was assayed by immunoblot using the anti-FKHRL1 antibody (bottom panel).
(C) CCL39 fibroblasts were transiently cotransfected with FKHRL1 plasmids (WT or mutants) and an empty vector (2) or a constitutively active
Akt construct (1) and were treated as in (B) for the right panel. Cell lysates were resolved by SDS±PAGE (6%) and immunoblotted with the
anti-HA antibody.
(D) CCL39 fibroblasts were serum starved for 20 hr, then incubated with 10 mM LY for 1 hr and stimulated with 50 ng/ml IGF1 or 20% FCS
for 20 min. Immunoblotting experiments were performed as in (B).
To determine whether FKHRL1 phosphorylation is in- The anti-phosphoantibodies that we generated to the
phosphopeptide that spans S315 were found not to beduced by the addition of survival factors, we expressed
HA-tagged FKHRL1 in the IGF1-responsive fibroblast site specific (data not shown). To assay Akt's ability to
catalyze the phosphorylation of FKHRL1 at S315, wecell line CCL39 and examined the phosphorylation sta-
tus of FKHRL1 using the phosphoantibodies in immu- took advantage of the finding that the presence of IGF1
or the expression of a constitutively active Akt inducednoblot experiments. We found that a 20 min exposure
of fibroblasts to IGF1 induced the phosphorylation of a shift up in the mobility of wt FKHRL1 on an SDS gel
(Figure 2C). When FKHRL1 S315 was mutated to anFKHRL1 at T32 and S253 (Figure 2B). To determine
whether IGF1 induction of FKHRL1 phosphorylation was alanine, Akt no longer induced a shift in FKHRL1 mobility
(Figure 2C). By contrast, mutating FKHRL1 T32 and S253mediated by the PI3K pathway, we examined the effect
of an inhibitor of PI3K, LY 294002 (LY), on FKHRL1 phos- to alanines had no effect on Akt's ability to induce a
shift in FKHRL1 mobility (Figure 2C). These findings indi-phorylation. The phosphorylation of both T32 and S253
was inhibited by LY treatment (Figure 2B), suggesting cate that the Akt-dependent shift in FKHRL1 mobility is
primarily due to the Akt-dependent phosphorylation ofthat the endogenous PI3K pathway is necessary for
FKHRL1 phosphorylation at T32 and S253 in vivo. FKHRL1 at S315. Although, as shown above, Akt phos-
phorylates FKHRL1 at T32 and S253, the phosphoryla-To determine whether Akt activity was sufficient to
mediate the effect of IGF1 on FKHRL1 phosphorylation, tion of these two sites appears not to have a significant
effect on the mobility of FKHRL1 on an SDS gel. Thewe cotransfected CCL39 cells with a constitutively ac-
tive mutant of Akt and the HA-tagged form of FKHRL1. expression of constitutively active Akt induces the phos-
phorylation of FKHRL1 at S315 in cells, but Akt doesWe found that the expression of this constitutively active
version of Akt induced the phosphorylation of FKHRL1 not effectively catalyze the phosphorylation of FKHRL1
at S315 in vitro. Thus, it is possible that within cells Aktat both T32 and S253 in vivo (Figure 2B, right panels),
indicating that active Akt alone is sufficient to induce activates one or more other kinases that then trigger
FKHRL1 phosphorylation at S315.the phosphorylation of FKHRL1 at T32 and S253 in vivo.
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Figure 3. Akt, by Phosphorylating FKHRL1, Promotes Its Retention in the Cytoplasm
(A and B) CCL39 fibroblasts were transiently transfected with the HA-tagged FKHRL1 construct (WT or triple mutant) and were either incubated
in the presence of 10% FCS, or serum starved for 20 hr and then incubated with 10 mM of LY for 1 hr. FKHRL1 was detected by immunolocalization
with the anti-HA antibody. Representative pictures are shown in (A), and quantitation of the experiment is shown in (B).
(C and D) CCL39 fibroblasts were cotransfected with a wt M2-tagged FKHRL1 construct and different constructs encoding either a dominant
interfering mutant form of Akt (Akt k.n.), a wild-type form of Akt (Akt WT), or a constitutively active version of Akt (Akt c.a.). Cells were either
incubated in the presence of serum or were serum starved for 20 hr and then incubated with 10 mM of LY for 1 hr. FKHRL1 was detected by
immunolocalization with the anti-M2 antibody. Representative pictures are shown in (C), and quantitation of the experiment is shown in (D).
We next asked whether the anti-FKHRL1 phosphoan- Genetic evidence obtained in C. elegans suggests that
the PI3K/Akt pathway acts to antagonize the functiontibodies could detect the endogenous form of FKHRL1
and whether endogenous FKHRL1 becomes newly phos- of the FKHRL1 homolog DAF16 in the nematode (Ogg
et al., 1997). There are several possible explanations forphorylated in response to external stimuli (Figure 2D).
By immunoblot experiments with the anti-phosphoanti- this genetic finding. For example, Akt might decrease
the total level of DAF16/FKHRL1 expression. Alterna-bodies, we found that exposure of CCL39 fibroblasts
to IGF1 induces the phosphorylation of a protein that tively, Akt might inhibit DAF16/FKHRL1 function as a
transcriptional activator or repressor by affecting eithercorresponds in molecular weight to FKHRL1 (100 kDa).
In addition, phosphorylation of the 100 kDa protein was DAF16/FKHRL1's nuclear localization, its binding to
DNA, its interaction with putative partners, or its intrinsicblocked when cells were treated with the PI3K inhibitor
LY (Figure 2D). Given the fact that the protein recognized transcriptional activation or repression function.
Since the expression of Akt did not significantly alterby the phosphoantibodies has the correct molecular
weight, it is likely that this protein is the endogenous the expression of FKHRL1 (see Figure 2B), we asked
whether Akt-induced phosphorylation of FKHRL1 mightFKHRL1 or a closely related protein. We conclude that
phosphorylation of an endogenous FKHRL1-related pro- have an effect on the subcellular distribution of this
transcription factor. Toward this end, we transfectedtein is induced by IGF1 by a PI3K-dependent mech-
anism. the HA-FKHRL1 into fibroblasts and examined FKHRL1
subcellular localization under different conditions ofTaken together, these experiments indicate that growth
factor activation of the PI3K/Akt pathway is both neces- PI3K/Akt activation (Figure 3). When the endogenous
PI3K/Akt pathway was inhibited (serum starvation andsary and sufficient to induce the phosphorylation of
FKHRL1 at T32, S253, and S315 within cells. treatment with LY), wild-type FKHRL1 was localized al-
most entirely within the nucleus (Figures 3A and 3B).
By contrast, when the PI3K/Akt pathway was activatedAkt Phosphorylated FKHRL1 Is Retained
in the Cytoplasm (treatment with 10% serum), wild-type FKHRL1 was
largely excluded from the nucleus and was detected inWe next investigated the effect of Akt phosphorylation
on the function of FKHRL1 as a transcription factor. the cytoplasm (Figures 3A and 3B).
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To determine whether the subcellular localization of
FKHRL1 was dependent upon Akt activation, we co-
transfected into fibroblasts different versions of HA-
tagged Akt together with an M2-tagged form of wild-
type FKHRL1 and assessed the effect of these proteins
on FKHRL1's subcellular localization (Figures 3C and
3D). When coexpressed with a constitutively active ver-
sion of Akt, FKHRL1 was excluded from the nucleus and
localized within the cytoplasm, even in the absence of
survival factors (Figure 3C, left panel). Conversely, when
coexpressed with a kinase-inactive version of Akt that
is known to inhibit the function of the endogenous Akt,
FKHRL1 was primarily localized within the nucleus, even
in the presence of survival factors (Figure 3C, right
panel). These experiments demonstrate that under these
conditions, Akt activity is both necessary and sufficient
to retain FKHRL1 in the cytoplasm.
To determine whether the effect of Akt on the subcel-
Figure 4. The Phosphorylated Form of FKHRL1 Binds to 14-3-3lular localization of FKHRL1 was due to the phosphoryla-
293T cells were transiently cotransfected with an empty vector (CTL)tion of FKHRL1, we examined the subcellular distribu-
or HA-tagged FKHRL1 constructs and a construct encoding the 14-tion of FKHRL1 mutants in which T32, S253, and/or
3-3 zeta isoform tagged with the M2 epitope. 14-3-3 was immuno-S315 was converted to an alanine (Figures 3A and 3B).
precipitated with the anti-M2 antibody, and the immune complex
Whereas the wild-type form of FKHRL1 was found to be was resolved by SDS±PAGE and immunoblotted with the anti-HA
predominantly cytoplasmic in cells exposed to serum, antibody (top panel). Total cell extracts were also analyzed by direct
immunoblotting with the anti-HA antibody (middle panel) or the anti-FKHRL1 in which T32, S253, and S315 were all converted
M2 antibody (bottom panel).to alanines was exclusively nuclear (Figures 3A and 3B).
This indicates that phosphorylation at these three sites
alters the subcellular distribution of FKHRL1. When not
To this end, we coexpressed FKHRL1 and the zeta iso-phosphorylated, FKHRL1 is localized to the nucleus. By
form of 14-3-3 in 293T cells in the presence of growthcontrast, when these three sites are phosphorylated,
factors. Immunoprecipitation experiments followed byFKHRL1 is retained in the cytoplasm.
immunoblotting showed that wild-type FKHRL1 inter-Detailed comparison of each of the FKHRL1 phos-
acts with 14-3-3 zeta (Figure 4). To determine whetherphorylation mutants revealed that when either T32,
the phosphorylation of FKHRL1 was critical for this inter-S253, or S315 was mutated to an alanine, the number
action, we tested the mutants of the FKHRL1 phosphor-of cells expressing FKHRL1 in the nucleus was substan-
ylation sites in the coimmunoprecipitation assay (Figuretially increased (data not shown). An analysis of the
4). The S315A mutant of FKHRL1 interacted with 14-3-3subcellular localization of the double mutants revealed
to the same extent as wild-type FKHRL1, indicating thatthat the mutation of two of the phosphorylation sites
the phosphorylation of S315 is not required for 14-3-3resulted in an even greater percentage of cells showing
binding. By contrast, both T32A and S253A single mu-FKHRL1 within their nucleus (data not shown), sug-
tants of FKHRL1 interacted less efficiently than wild-gesting that phosphorylation of FKHRL1 at all three sites
type FKHRL1 with 14-3-3. Moreover, the interaction ofis necessary to retain FKHRL1 completely within the
FKHRL1 with 14-3-3 was abolished when T32 and S253cytoplasm.
of FKHRL1 were both converted to alanines, indicatingTaken together, these findings indicate that growth
that phosphorylation of both sites contributes to 14-3-3factor stimulation via the endogenous PI3K/Akt pathway
binding. These findings suggest that Akt may pro-induces the phosphorylation of FKHRL1 at three sites
mote FKHRL1's interaction with 14-3-3 by phosphorylat-that play an important role in sequestering FKHRL1 in
ing FKHRL1 at T32 and S253. Thus, in growth factor±the cytoplasm, away from FKHRL1's target genes in the
stimulated cells, a function of 14-3-3 may be to bind thenucleus.
phosphorylated form of FKHRL1 and thereby sequester
FKHRL1 in the cytoplasm so that it is unable to regulate
its target genes in the nucleus.Phosphorylated FKHRL1 Binds to 14-3-3
We next considered the possibility that the phosphoryla-
tion of FKHRL1 might cause FKHRL1 sequestration in Identification of DNA-Binding Sites for FKHRL1
the cytoplasm by promoting FKHRL1's interaction with a To address FKHRL1's mechanism of action within the
protein that functions as a scaffold within the cytoplasm. nucleus, we first examined the ability of FKHRL1 to inter-
One group of scaffolding proteins that specifically bind act with specific DNA sequences using a DNA mobility
certain phospho-serine-containing proteins is the 14- shift assay. Although FKHRL1 contains a ªForkhead do-
3-3 family of proteins. Given that the amino acid se- mainº that has been shown to be a DNA-binding domain
quence surrounding T32 is a perfect consensus site for for all FH family members, it had not been determined
14-3-3 binding, except for the substitution of a Thr for whether FKHRL1 or DAF16 interacts directly with DNA.
a Ser (Yaffe et al., 1997), we investigated whether the Moreover, the sequence of DNA recognized by FKHRL1
remained to be identified.T32 phosphorylated form of FKHRL1 binds to 14-3-3.
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of an excess of a mutant DNA sequence (Figure 5B,
lanes 6, 7, 8 and data not shown). In the presence of
the anti-FKHRL1 antibody, but not a control antibody,
the shifted band was supershifted (Figure 5B, lanes 4
and 5), demonstrating that the shifted band was due
to the binding of FKHRL1 to the IRS element. Similar
experiments performed with the FHRE showed that
FKHRL1 was also able to bind this site (data not shown).
Taken together, these DNA mobility shift experiments
indicate that FKHRL1 is capable of binding to a specific
DNA sequence element that conforms to the consensus
regulatory element recognized by Forkhead transcrip-
tion factors.
FKHRL1, When Not Phosphorylated by Akt,
Is an Activator of Transcription
We next asked whether FKHRL1 regulates transcription
when bound to an FH recognition site within the pro-
moter of a reporter gene and, if so, what effect Akt-
induced phosphorylation of FKHRL1 has on this process.
Two models of transcriptional regulation are possible to
Figure 5. FKHRL1 Is Able to Bind Two Elements on DNA account for the genetic findings obtained in C. elegans.
(A) Comparison between the consensus Forkhead-binding sites and First, DAF16 and its human counterparts might be acti-
sites found in the IGFBP1 or in the Fas ligand promoter. The under- vators of transcription, and Akt, by inhibiting their func-
lined nucleotides match the Forkhead consensus. tion, might turn off gene expression. Alternatively, DAF16
(B) 293T cells were transiently transfected with FKHRL1 wt or triple
and related proteins might be repressors of transcrip-mutant. Whole-cell extracts were assayed in band shift experiments
tion, and Akt, by suppressing the activity of a transcrip-using the IRS of IGFBP1 as the 32P-labeled oligonucleotide. For
supershift experiments, immunopurified antibodies to either FKHRL1 tional repressor, might turn on gene expression. To dis-
or the nonrelated factor ATF1 were added to the extracts 10 min tinguish between these two possibilities, we generated
before adding the probe. ªAº indicates the supershifted FKHRL1/ a reporter construct in which a small region of the Fas
IRS complex; ªB,º the specific FKHRL1/IRS complex; and ªC,º a ligand promoter containing the three canonical FHREs
nonspecific protein/DNA complex.
was inserted 59 of a basal promoter controlling the ex-
pression of the luciferase gene (FHRE-Luc reporter). The
effect of FKHRL1 on reporter gene transcription wasWe searched for DNA sequences that are similar to the
assessed after cotransfection of FKHRL1 and the lucifer-previously characterized Forkhead consensus binding
ase reporter gene into cells (Figure 6).sites (Pierrou et al., 1994; Kaufmann et al., 1995) within
We found that in the absence of survival factors, wild-promoters of growth factor±responsive genes (Figure
type FKHRL1, which is nuclear under these conditions,5A). One element that matched the FH consensus ele-
effectively induced luciferase reporter gene expressionment was the insulin-responsive sequence (IRS) that
(Figure 6A), indicating that FKHRL1 is an activator ratherhad been identified in the promoter of several genes
than a repressor of transcription. In the presence ofrepressed by insulin in a PI3K/Akt-dependent manner,
IGF1, the expression of the FHRE-Luc reporter gene bysuch as insulin-like growth factor±binding protein 1
FKHRL1 was significantly reduced (Figure 6A), suggesting(IGFBP1) (Cichy et al., 1998) (Figure 5A). We also identi-
that the PI3K/Akt pathway plays a role in inhibitingfied a cluster of three perfect consensus sites for FH
FKHRL1-dependent transcription. This was confirmedfactor binding within the promoter of the Fas ligand
by the finding that FKHRL1-dependent transcriptiongene, termed the FH-responsive element (FHRE) (Holtz-
was dramatically suppressed when FKHRL1 was coex-Heppelmann et al., 1998) (Figure 5A). Transcription of
pressed with a constitutively active form of Akt and thethe Fas ligand gene has recently been found to be in-
FHRE-Luc reporter gene (Figure 6B).duced when neurons are deprived of survival factors
To determine whether the effect of Akt on FKHRL1-(Le-Niculescu et al., 1999).
dependent transactivation was due to Akt's ability toTo determine whether FKHRL1 is able to bind to the
phosphorylate FKHRL1, we cotransfected the FHRE-IRS or the FHRE, we performed DNA mobility shift exper-
Luc reporter with a mutant form of FKHRL1 in which alliments using oligonucleotides corresponding to an IRS
three of the Akt phosphorylation sites were converted(Figure 5B) or the FHRE (data not shown) and whole
to alanines. The triple mutant of FKHRL1, which local-cells extracts prepared from 293T cells transfected with
ized to the nucleus, potently induced transcription of theFKHRL1 (wild type or triple mutant). We found that both
reporter gene even in the presence of IGF1, a conditionthe wild-type and the triple mutant form of FKHRL1
under which the endogenous PI3K/Akt pathway is activebound to the IRS of the IGFBP1 gene, leading to a shift in
(Figure 6C). The ability of the triple mutant of FKHRL1the mobility of the IRS DNA element on a nondenaturing
to induce the expression of the FHRE-Luc reporter genepolyacrylamide gel (Figure 5B, lanes 1, 2, and 3). Forma-
was not affected by the status of Akt activity. First, thetion of the FKHRL1/IRS complex was inhibited by an
excess of unlabeled IRS DNA but not by the inclusion transactivating effect of the triple mutant of FKHRL1
Akt Phosphorylates FKHRL1
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Figure 6. FKHRL1 Activates Reporter Gene
Transcription, and This Activity Is Sup-
pressed by Akt in a Phosphorylation-Depen-
dent Manner
(A) CCL39 fibroblasts were transiently cotrans-
fected with an empty vector (CTL) or a vector
encoding wild-type FKHRL1 together with the
luciferase reporter construct under the con-
trol of the portion of the Fas ligand promoter
that contains three FH-binding sites (FHRE-
Luc reporter). One day after transfection, cells
were incubated in the presence or absence
of IGF1 for 24 hr, and the luciferase activity
was assayed.
(B) CCL39 fibroblasts were transiently cotrans-
fected with an empty vector (CTL) or a vector
encoding wild-type FKHRL1 together with a
constitutively active form of Akt and the
FHRE-Luc reporter. The cells were incubated
in serum-free medium for 24 hr, and luciferase
assays were performed.
(C) CCL39 fibroblasts were transiently cotrans-
fected with an empty vector (CTL), or a vector
encoding FKHRL1 wt or the triple mutant (TM)
and the FHRE-Luc reporter. Cells were incu-
bated in the presence of IGF1 for 24 hr, and
luciferase assays were performed.
(D) The same experiment as in (A) was per-
formed with the empty vector (CTL) or the wt
and the triple mutant (TM) of FKHRL1. The
results are presented as fold inhibition by
IGF1.
(E) The same experiment as in (B) was performed with the empty vector (CTL) or the wt and the triple mutant (TM) of FKHRL1. The results
are presented as fold inhibition by Akt.
Data presented represent the mean and SEM of three (B and D) or four (A and C) independent experiments conducted in duplicate. Each bar
is statistically significant according to ANOVA with p , 0.01.
was independent of the presence or absence of IGF1 production of Fas ligand is important for apoptosis in-
duced by the withdrawal of survival factors, since(Figure 6D). Second, the expression of a constitutively
active form of Akt failed to efficiently suppress the induc- blocking the action of Fas ligand leads to a reduction
in apoptosis (Le-Niculescu et al., 1999). We found thattion of the FHRE-Luc reporter gene by the triple mutant
of FKHRL1 (Figure 6E). the Fas ligand promoter contains within its regulatory
region three FHREs that bind FKHRL1 (Figure 5) andTaken together, these experiments indicate that in the
absence of phosphorylation by Akt, FKHRL1 acts in the mediate FKHRL1-dependent transcription (Figure 6).
Moreover, using a construct in which 2.5 kb of the Fasnucleus as an activator of transcription. By catalyzing
the phosphorylation of FKHRL1, Akt prevents FKHRL1- ligand promoter was fused to the luciferase reporter
gene, we found that the triple mutant of FKHRL1 induceddependent transcription mainly by promoting the exclu-
sion of FKHRL1 from the nucleus so that this transcrip- the activity of the Fas ligand native promoter (data not
shown).tion factor is unable to activate its target genes.
To examine the effect of FKHRL1 on apoptosis, we
first used cerebellar granule neurons as a cellular modelThe Nonphosphorylated Form of FKHRL1 Induces
Apoptosis by a Fas Ligand±Dependent Mechanism for apoptosis, since these cells have been shown both
to be dependent on Akt activity for their survival and onWe observed that FKHRL1 bound to DNA and activated
transcription under conditions of growth factor with- Fas ligand for apoptosis. We transfected these neurons
with the wild-type or the triple mutant form of FKHRL1drawal that can lead to apoptosis. This finding prompted
us to consider whether FKHRL1 might regulate the and performed a blind analysis of cell survival and apo-
ptosis in the transfected cells by microscopic visualiza-expression of critical death genes and thereby induce
apoptosis. Akt might then promote survival by phos- tion of the integrity of the nucleus and the processes
as previously described (Dudek et al., 1997) (Figure 7A).phorylating FKHRL1 and inhibiting its function as a tran-
scriptional activator. These experiments showed that in the presence of the
survival factor IGF1, the triple mutant of FKHRL1, whichOne possible FKHRL1 target whose protein product
is a mediator of cell death is the Fas ligand gene. We is no longer phosphorylated by Akt and is localized to
the nucleus, induced apoptosis when compared to aand others have found that the withdrawal of growth
factors from several different cell types, including PC12 control empty vector or wt FKHRL1 (Figure 7A, left
panel). The effect of mutant FKHRL1 on apoptosis wascells and cerebellar granule neurons, leads to the upreg-
ulation of Fas ligand mRNA and protein (Le-Niculescu also observed in other cell types such as Jurkat T lym-
phocytes (Figure 7C), which are also extremely sensitiveet al., 1999; G. Perini, et al., unpublished data). The
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to Fas signaling (Nagata, 1997), and CCL39 fibroblasts
(Figure 7A, right panel).
To determine whether the induction of cell death by
the triple mutant was mediated at least in part by its
ability to induce the expression of the Fas ligand gene,
we used two different approaches to block the Fas li-
gand signaling. The first approach employed a soluble
Fas-Fc fusion protein that functions as a decoy for the
newly synthesized Fas ligand and thus inhibits Fas li-
gand binding to its cell surface receptor Fas (Nagata,
1997). When cerebellar granule neurons were treated
with Fas-Fc, but not with the control Fc, the FKHRL1-
induced apoptosis was significantly reduced (Figure
7B). The inhibition of FKHRL1-induced apoptosis by
Fas-Fc was specific, since Fas-Fc treatment did not
affect the basal level of apoptosis nor the apoptosis
induced by the expression of Caspase 8, a downstream
component of the Fas signaling cascade (Figure 7B).
The blocking effect of Fas-Fc on the apoptosis caused
by the triple mutant of FKHRL1 was also observed in
CCL39 fibroblasts (data not shown).
The second approach we employed to assess the
importance of Fas ligand for FKHRL1-induced apoptosis
took advantage of mutant cell lines derived from Jurkat
cells that are functionally deficient in the receptor Fas
or in a crucial component of the Fas signaling cascade,
the adaptor protein FADD (P. J. and J. B., unpublished
data). In wt Jurkat cells, as in neurons and fibroblasts,
the triple mutant of FKHRL1 induced a high level of
apoptosis relative to the control vector (Figure 7C). The
apoptotic effect of the triple mutant of FKHRL1 was
almost completely abolished when mutant FKHRL1 was
expressed in Fas or FADD mutant Jurkat cells (Figure
7C), indicating that the Fas signaling cascade is required
for FKHRL1 induction of apoptosis.
Discussion
Figure 7. The Nonphosphorylatable Form of FKHRL1 Triggers Apo-
ptosis by a Fas Ligand±Dependent Mechanism
Growth factors promote cell survival at least in part by
(A) (Left) Cerebellar granule cells were transiently cotransfected with activating the PI3K and its downstream target Akt. Onean empty vector (CTL), or a vector encoding FKHRL1 wt or the triple
function of Akt is to phosphorylate and inhibit proapo-mutant (TM) and a vector encoding b-galactosidase. After 24 hr,
ptotic components of the intrinsic cell death machinerycells were incubated for 20 hr with IGF1. Transfected cells were
stained with the anti-b-galactosidase antibody, and DNA was present within the cytoplasm. There is evidence that the
stained with Hoechst. The experiments were performed in duplicate, PI3K/Akt pathway may also have an important function
and 100 to 200 cells per coverslips were counted in a blinded fash- within the nucleus (Lin et al., 1997; Ogg et al., 1997;
ion. Data presented correspond to the mean and SEM of three Cichy et al., 1998). However, the nuclear targets of theindependent experiments. The results comparing the triple mutant
PI3K/Akt pathway and their role in cell survival are notto the empty vector and the wt were statistically significant ac-
yet well clarified. In this study, we demonstrate that thecording to ANOVA with p , 0.01.
(Right) CCL39 fibroblasts were transfected and scored for apoptosis PI3K/Akt pathway regulates transcription by phosphory-
as described for neurons in left panel. Data presented represent the lating FKHRL1, a member of the Forkhead transcription
mean and variation of two independent experiments performed in factor family. This leads to FKHRL1's interaction with
duplicate. 14-3-3 proteins and FKHRL1's sequestration in the cyto-(B) Cerebellar granule cells were transiently cotransfected with a
plasm, away from its transcriptional targets. Under con-vector encoding the b-galactosidase and with an empty vector
ditions of growth factor deprivation, the PI3K/Akt path-(CTL), a vector encoding the triple mutant of FKHRL1 (TM) or the
vector encoding Caspase 8. Cells were incubated with Fas-Fc or a way is inactivated, FKHRL1 is unphosphorylated at its
control Fc (1 mg/ml) for 20 hr and apoptotic cells scored in a blinded Akt sites, and FKHRL1 accumulates in the nucleus
fashion as described in (A). Data presented correspond to the mean where it may activate death genes, including the Fas
and SEM of three independent experiments performed in duplicate.
The results comparing the effect of control Fc and Fas-Fc for the
triple mutant are statistically significant according to ANOVA with
p , 0.05.
(C) Jurkat T cells (WT, FADD mutant [FADDm], or Fas mutant [Fasm]) eight hours after transfection, cells were stained with Hoechst and
were cotransfected with an empty vector (CTL) or a vector encoding apoptotic cells were counted. Data presented represent the mean
the triple mutant of FKHRL1 (TM) and a vector encoding GFP. Forty- and variation of two independent experiments.
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ligand gene, and thereby participate actively in the pro- gene. This suggests that under certain circumstances,
FKHRL1 may control the expression of the endogenouscess of apoptosis.
When fibroblasts are exposed to IGF1 or serum, Akt Fas ligand gene. Consistent with this possibility, we find
that a mutant form of FKHRL1 that is not phosphorylatedis activated and catalyzes the phosphorylation of FKHRL1.
It is likely that additional protein kinases whose consen- by Akt induces apoptosis by a Fas ligand±dependent
mechanism. Additional experiments will be required tosus sites of phosphorylation are similar to that of Akt,
such as PKA or p90RSK, may regulate FKHRL1 function determine whether the endogenous FKHRL1 also regu-
lates Fas ligand transcription and cell death. Since theby phosphorylating FKHRL1 at T32, S253, and/or S315.
Moreover, an analysis of the amino acid sequence of Fas ligand gene has previously been shown to be regu-
lated by a number of transcription factors also involvedFKHRL1 reveals the presence of potential phosphoryla-
tion sites in addition to T32, S253, and S315. For exam- in cell death regulation, including NFAT (Latinis et al.,
1997; Faris et al., 1998; Holtz-Heppelmann et al., 1998),ple, FKHRL1 contains several serines and threonines
that are flanked by amino acids that conform to the AP1 and NFkB (Kasibhatla et al., 1998), and Egr3 (Mittel-
stadt and Ashwell, 1998), it is possible that FKHRL1 willconsensus site (PXS/TP) recognized by MAP kinases.
Further studies will be required to determine whether be found to cooperate with one or several of these other
factors to induce Fas ligand transcription and apoptosisprotein kinases in addition to Akt play an important role
in regulating FKHRL1 function. in growth factor±deprived cells. One way Akt might sup-
press apoptosis would be to inhibit one or several tran-The phosphorylation of FKHRL1 at T32 and S253 pro-
motes FKHRL1 binding to the zeta isoform of 14-3-3. scription factors that control the expression of death
genes such as the gene encoding Fas ligand.The interaction of FKHRL1 with 14-3-3 may be important
for retaining the phosphorylated form of FKHRL1 in the Although we present evidence that in postmitotic neu-
rons, fibroblasts, or Jurkat T cells, the nonphosphory-cytoplasm and thereby for inhibiting FKHRL1's ability
to activate transcription. In addition, the binding of lated form of FKHRL1 plays a role in mediating cell
death, it is likely that FKHRL1 in mammals and DAF16FKHRL1 to 14-3-3 in growth factor±stimulated cells may
prevent the dephosphorylation of FKHRL1 by endoge- in C. elegans have other biological functions as well. In
fibroblasts that have been deprived of serum and havenous phosphatases and in this way may prolong the
action of Akt and promote cell survival. withdrawn from the cell cycle into the G0 resting state,
the PI3K/Akt pathway is inactive and FKHRL1 is local-It is not clear how the withdrawal of survival factors
triggers the dephosphorylation and relocalization of ized to the nucleus. It is possible that under these cir-
cumstances, FKHRL1 actively induces the expressionFKHRL1 to the nucleus. The dephosphorylation of FKHRL1
may reflect the inactivation of Akt permitting the action of genes that inhibit cell cycle progression, such as the
CDK inhibitors. A role for FKHRL1 in apoptosis and cellof a constitutively active protein phosphatase on the
transcription factor. cycle control is consistent with the observation that mu-
tations of FKHRL1 can lead to oncogenesis (Hillion etThere are several mechanisms that may explain how
the unphosphorylated form of FKHRL1 translocates to al., 1997; Anderson et al., 1998).
It is also likely that in certain cell types, FKHRL1 regu-the nucleus where it activates gene expression. An anal-
ysis of other FH family members has revealed the pres- lates the expression of genes that modulate metabolic
functions of the cell. For example, in mammals as wellence of a domain enriched in basic amino acids at the
end of the FH DNA±binding domain that may form part as in C. elegans, the PI3K/Akt pathway has been found
to mediate aspects of the cellular response to insulin.of a nuclear localization signal (NLS). Since in FKHRL1
this basic domain overlaps with the second site of Akt One of the sites to which FKHRL1 binds is present within
the regulatory region of a number of genes whose tran-phosphorylation (S253), it is possible that phosphoryla-
tion of this site adds a negative charge to the positively scription is repressed by insulin in a PI3K/Akt-depen-
dent manner, such as IGF-BP1 or phosphoenolpyruvatecharged basic region, thereby disrupting the function
of the NLS. In growth factor±deprived cells, when Akt carboxykinase (PEPCK) (O'Brien et al., 1995; Cichy et
al., 1998; Liao et al., 1998). It is possible that the down-is inactive and FKHRL1 is dephosphorylated, the NLS
may function effectively and thus promote the transloca- regulation of genes by insulin also involves the phos-
phorylation and cytoplasmic sequestration of FKHRL1tion of FKHRL1 to the nucleus. An alternative possibility
is that the phosphorylation of FKHRL1 changes FKHRL1's or closely related transcription factors. Therefore, the
PI3K/Akt signaling pathway, by phosphorylating FKHRL1,interaction with other proteins that act either to seques-
ter FKHRL1 in the cytoplasm when FKHRL1 is phosphor- may coordinately regulate the expression of proapo-
ptotic genes, cell cycle±regulated genes, and genes thatylated (e.g., 14-3-3) or to localize the unphosphorylated
form of FKHRL1 within the nucleus. control cellular homeostasis. It will be of interest in the
future to determine the complete array of genes that areOnce FKHRL1 is in the nucleus, it binds to specific
DNA sequence elements and functions as an activator regulated by FKHRL1.
It is suggested by the experiments reported here thatrather than as a repressor of transcription. Our experi-
ments demonstrate that nuclear FKHRL1 binds to a DNA Akt regulates a variety of biological processes in mam-
mals by phosphorylating FKHRL1. It is likely that in C.sequence, the Forkhead response element (FHRE),
which is found in three copies within the regulatory re- elegans, Akt phosphorylation of DAF16 leads to the relo-
calization of DAF16 within the cell from the nucleus togion of the Fas ligand gene. Under conditions of cell
growth where the PI3K/Akt pathway is inactive and the cytoplasm, thereby providing a biochemical mecha-
nism for the genetic finding that Akt antagonizes DAF16FKHRL1 is unphosphorylated, FKHRL1 effectively pro-
motes the transcription of an FHRE-driven reporter function. That many aspects of the PI3K/Akt/FKHRL1
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SDS±PAGE (12%) and 32P-labeled proteins visualized by autoradiog-signaling pathway are conserved in organisms as di-
raphy.verse as C. elegans and mammals indicates that this
signal transduction pathway will prove to be critical for
Immunoblotting and Immunoprecipitationthe proper development and function of most, if not all,
Cells were seeded in 6-well dishes at the density of 5.105 cells/well.animal species.
They were transfected with 5 mg of the FKHRL1 construct. Twenty-
four hours after transfection, cells were incubated in serum-free
Experimental Procedures DMEM for 20 hr and stimulated with IGF1. Extracts were prepared
for immunoblotting or immunoprecipitation using Triton lysis buffer
Materials as described previously (PageÁ s et al., 1994).
IGF1 and LY 294002 (LY) were purchased from Boehringer Mann-
heim and Calbiochem, respectively. Unless otherwise stated, IGF1
Immunolocalizationand LY were used at the final concentrations of 50 ng/ml and 20
CCL39 cells were plated onto glass coverslips at a density of 105mM, respectively. The anti-HA and the anti-M2 monoclonal antibod-
cells/well in 12-well dishes. The cells were transfected with 4 mg ofies were obtained from Boehringer Mannheim and Kodak, respec-
the indicated plasmid. The day after transfection, cells were incu-tively. The anti-ATF1 antibody was purchased from UBI. The Fas-
bated in serum-free medium for 16 hr, and then treated with 10 mMFc fusion protein was obtained from R&D Systems and used at the
LY for 1 hr. The cells were then fixed in 4% formaldehyde/2% su-final concentration of 1 mg/ml.
crose and permeabilized with 0.1% Triton X100. Coverslips were
incubated with the primary antibodies (anti-HA or anti-M2) for 2 hr,
Constructs then incubated for 1 hr with a goat anti-mouse cy3-conjugated
The vector encoding the HA-tagged forms of Akt, either constitu- antibody. Coverslips were mounted in Vectastain (Vector Labora-
tively active (myristylated-DPH) or inactive (KM mutant), and the tories) and examined under epifluorescent illumination. For quantita-
CMV-LacZ, EF-LacZ, and CMV-GFP constructs used in this study tion, 50±100 cells per coverslip were counted.
have been described previously (Datta et al., 1997; Dudek et al.,
1997). The vector encoding mouse Caspase 8 (Sakamaki et al., 1998)
Electrophoretic Mobility Shift Assaywas kindly provided by Dr. S. Yonehara. The vector encoding the
293T cells were seeded in 6-well plates at a density of 750,000 cells/M2-tagged form of the zeta isoform of 14-3-3 was kindly provided
well. 293T cells were transfected with 2.5 mg of the various FKHRL1by Dr. H. Fu. The FKHRL1 human cDNA (Anderson et al., 1998) was
plasmids and 2.5 mg of the plasmid encoding the constitutivelytagged at the N terminus with the HA epitope and subcloned into
active form of Akt. Whole-cell extracts were prepared by lysingthe pECE expression vector (Ellis et al., 1986). The mutants of each
the cells in a Triton lysis buffer as described (PageÁ s et al., 1994).FKHRL1 phosphorylation site were generated by PCR. The wild-
Complementary oligonucleotides corresponding to the IGFBP1 IRStype FKHRL1 cDNA was tagged at the C terminus with the M2
(59-ATTGCTAGCAAGCAAAACAAACCGCTAGCTTA-39) or the Fas li-epitope and subcloned into a modified version of the pcDNAneo3
gand site (59-AATAGATCTTAAATAAATAGATCTTTA-39) were an-expression vector. The cDNA encoding the first 525 amino acids
nealed and end-labeled with g32P ATP. The binding reactions wereor full-length FKHRL1 were subcloned into the pGex 4T3 vector
performed and analyzed on a nondenaturing gel as described (Pier-(Pharmacia). Details of the constructs are available upon request.
rou et al., 1994). For supershift studies, 1 ml of immunopurified anti-Wild-type and mutant GST-FKHRL1 protein were prepared ac-
FKHRL1 antibody or the anti-ATF1 antibody was preincubated forcording to the Pharmacia protocol.
10 min on ice with the cell extract. DNA±protein complexes wereA 2.5 kb fragment of the human Fas ligand promoter was kindly
visualized by autoradiography.provided to us by Dr. C. V. Paya (Holtz-Heppelmann et al., 1998). The
fragment of the Fas ligand promoter containing the three FKHRL1-
binding sites located between nucleotides 2743 to 2648 relative Luciferase Assay
to the start site of Fas ligand mRNA synthesis initiation was amplified CCL39 cells were seeded in 24-well plates, at a density of 105 cells/
by PCR and subcloned between the NheI and BglII site of the pGL3 well, and were cotransfected with 0.25 mg of the FKHRL1 plasmid
vector containing a minimal SV40 promoter (Promega). of interest, 0.5 mg of the Luciferase reporter gene, 0.25 mg of the
EF-LacZ construct, and 1 mg of carrier DNA (pBluescript). Two days
Antibodies after transfection, cells were lysed in 100 ml of lysis buffer, and the
Phosphopeptides of the following sequence were synthesized (Tufts luciferase activity of one-fifth of the samples was assayed according
Synthesis Facility, Boston, MA) (P-T32: CPQSRPRSCpTWPLQ; to the Promega protocol. b-galactosidase activity was assayed as
P-S253: CKAPRRRAVpSMDNS; P-S315: CTDFRSRTNpSNAST) and described (Maniatis et al., 1989).
coupled to KLH (Pierce). Antibodies to the KLH-coupled peptides
and purified full-length GST-FKHRL1 were obtained and purified as
Survival Assayspreviously described (Datta et al., 1997).
Cerebellar granule neurons were seeded onto glass coverslips in
24-well plates at a density of 107 cells/well and at DIV5-6 were
Cell Culture cotransfected with 2 mg of the construct of interest, 1 mg of the
The 293T human epithelial kidney cell line and the Chinese hamster CMV-GFP plasmid, and 0.5 mg of the CMV-LacZ plasmid as de-
lung fibroblast cell line CCL39 (ATCC) were cultured in DMEM sup- scribed (Dudek et al., 1997). Twenty-four hours after transfection,
plemented with 10% FCS (GIBCO) and antibiotics (50 U/ml penicillin cells were incubated for 20 hr in the presence of IGF1 and incubated
and 50 mg/ml streptomycin). Jurkat T lymphocytes were cultured or not with Fas-Fc or Fc alone (1 mg/ml). The transfected neurons
in RPMI supplemented with 10% FCS and antibiotics. Cerebellar were then fixed in 4% paraformaldehyde/2% sucrose. Immunofluo-
granule cells were obtained from P6 Long Evans rats and cultured rescence analyses were performed as described above using the
as previously described (Dudek et al., 1997). Unless otherwise anti-b-galactosidase antibody (Pharmacia), and nuclei were stained
stated, cells were transfected by the calcium phosphate technique. by Hoechst 33258 (2.5 mg/ml). Apoptotic nuclei were counted in a
blinded manner.
CCL39 fibroblats were transfected with 4 mg of the relevant plas-Kinase Assays
293T cells were seeded in 35 mm dishes at the density of 750,000 mid and 1 mg of the plasmid encoding GFP. They were treated in
the same way as described for neurons, and apoptotic nuclei ofcells per dish. They were transfected with 5 mg of the HA-Akt expres-
sion vectors. Twenty-four hours after transfection, cells were starved GFP-positive cells were counted in a blinded manner.
Jurkat cells were transfected by electroporation (250 V, 950 mF,in serum-free medium for 20 hr. Extracts were obtained and kinase
assays were performed as described (Dudek et al., 1997) using 5 Biorad) with 16 mg of the relevant plasmids and 4 mg of the plasmid
encoding GFP. GFP-positive cells were scored for apoptosis asmg of purified GST protein as a substrate and 5 mCi, 50 mM of
g32P ATP for 1 hr at 308C. The reaction products were resolved by described above.
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